Press Releases for SNTA

Press Releases
Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
Synta Pharmaceuticals Reports Second Quarter 2009 Financial Results
Synta Pharmaceuticals to Host Second-Quarter 2009 Conference Call on August 4, 2009
Synta Pharmaceuticals Names Vojo Vukovic, M.D., Ph.D. Senior Vice President and Chief Medical Officer
Synta and GSK End Elesclomol Collaboration Agreement
Synta Pharmaceuticals Announces Presentation of Preliminary Results of Phase 3 SYMMETRY Trial of Elesclomol in Metastatic Melanoma at ASCO 2009
Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Synta Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
Synta Pharmaceuticals Reports First Quarter 2009 Financial Results
Synta Pharmaceuticals to Host First-Quarter 2009 Conference Call on May 7, 2009
Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva®)-resistant Lung Cancer Models
Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results
Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2008 Conference Call on March 26, 2009
Synta Pharmaceuticals Initiates Phase 1/2 Clinical Trial of STA-9090 in Hematologic Malignancies
Synta Restructures Organization to Focus on New Priorities
Synta Postpones Release of 2008 Year-End Financial Statements and Conference Call
Synta Suspends Elesclomol SYMMETRYSM Trial in Metastatic Melanoma
Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2008 Conference Call on March 12, 2009
Synta Earns $10 Million from GlaxoSmithKline for Achieving Elesclomol Milestone
Synta Pharmaceuticals to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference
Research and Markets: Pipeline Insight: Cancer Overview: 6 Tumor Types Covered in This Report Are Forecast to Account for 961,000 New Cases of Cancer and $4,789m in Sales By 2017
Synta Pharmaceuticals Announces First Patient Treated in Elesclomol Monotherapy Solid Tumor Clinical Study
Synta Pharmaceuticals Names Dr. Vojo Vukovic, Vice President, Clinical Research
Synta Completes Enrollment of the Phase 3 SYMMETRYSM Trial of Elesclomol in Stage IV Metastatic Melanoma
Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2009
Synta and Roche Form Discovery, Development, and Commercialization Alliance in Inflammation
Synta Announces Continuation of the SYMMETRYSM Trial Based on Evaluation of Independent Data Monitoring Committee
Synta Earns $15 Million from GlaxoSmithKline for Achieving Elesclomol Milestones
Synta Pharmaceuticals to Participate in the RBC Capital Markets Healthcare Conference
Synta Pharmaceuticals to Present at the Piper Jaffray Annual Health Care Conference
Synta Pharmaceuticals Announces First Patient Treated in Phase 1/2 Clinical Trial of Elesclomol in Prostate Cancer
Learn About the World Investment Services Market Brief
Synta Pharmaceuticals Reports Third Quarter 2008 Financial Results
Synta Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Conference
Synta Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Synta Pharmaceuticals to Host Third-Quarter 2008 Conference Call on November 13, 2008
Synta Earns $25 Million from GlaxoSmithKline for Achieving Elesclomol Milestones
Synta Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference
Elesclomol Two-Year Survival and Integrated Safety Data Presented at the 33rd Congress of the European Society for Medical Oncology
Synta Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Synta Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Synta Announces Publication of Elesclomol Mechanism of Action Results in AACR Journal Molecular Cancer Therapeutics
Synta Pharmaceuticals Reports Second Quarter 2008 Financial Results
Synta Pharmaceuticals to Host Second-Quarter 2008 Conference Call on August 7, 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Synta Pharmaceuticals Corp.'s CEO Safi Bahcall Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner in New England
Synta Pharmaceuticals to Present at the 4th Annual Collins Stewart Growth Conference - Jun 26 2008 8:49AM
Synta Pharmaceuticals to Present at the 4th Annual Collins Stewart Growth Conference - Jun 26 2008 8:48AM
Wall Street Media Presents Five Exclusive Videos from the Needham Biotech Conference
Synta Pharmaceuticals to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
Synta Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference - May 27 2008 1:00AM
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma - May 27 2008 12:58AM
Synta Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 2 2008 4:23AM
Synta Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference - Jun 2 2008 4:23AM
Synta Pharmaceuticals Added to NASDAQ Biotechnology Index - Jun 2 2008 4:23AM
Semi-Annual Changes to the NASDAQ Biotechnology Index
Synta Pharmaceuticals to Host First-Quarter 2008 Conference Call on May 14, 2008 - Jun 2 2008 4:23AM
Synta Pharmaceuticals to Present at the Deutsche Bank Securities 33rd Annual Health Care Conference